NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Anaveon

Anaveon

Private
BaselHealthcare & Life Scienceshttps://anaveon.com/

Last Round

Series B

Dec 16, 2021

Est. Valuation

$248.5M

Total Funding Raised

$155.17M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Anaveon is a biotechnology company that develops next-generation precision biologics designed to selectively modulate the immune system for the treatment of autoimmune and inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyoncologycytokine therapyinterleukin-2IL-2clinical-stage biotechdrug discoveryclinical trialsbiologicsimmunologycancer drugbiotech startuplicensing agreementpharma partnershiptherapeutic assets

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Anaveon Comparables

Compare Anaveon with similar companies based on industry and business-model similarity.

Anaveon comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Synthekine
83%
Aulos Bioscience
80%
Medicenna Therapeutics Corp
78%

Anaveon Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BDec 16, 2021
Series AFeb 26, 2019
GrantDec 1, 2017

Key People

Founding team and executive leadership

Thaminda Ramanayake

Chief Executive Officer

Executive Team

Anaveon Investors

Notable investors and investment history

Anaveon investors
InvestorRounds
Forbion Capital PartnersSeries B
ForbionSeries B
SynconaSeries B, Series A
Pontifax Venture CapitalSeries B
Pontifax CreditSeries B
TD SecuritiesSeries B
Blue Owl CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 23, 2026

    Thaminda Ramanayake appointed as new Chief Executive Officer.

  • Feb 26, 2019

    $35M round led by Syncona.

Anaveon Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Anaveon Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Anaveon's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range25
Year Founded2017
Last FundingDec 16, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.